Summary
The novel coronavirus (SARS-CoV-2), identified in China at the end of the December 2019 is causing a potentially fatal respiratory syndrome (COVID-19), has meanwhile led to outbreak all over the globe. India has now become the third worst hit country globally with 16,38,870 confirmed cases and 35,747 confirmed deaths due to COVID-19 as of 31 July 2020. In this paper we have used mathematical modelling approach to study the effects of lockdowns and un-lockdowns on the pandemic evolution in India. This, study is based on SIDHARTHE model, which is an extension of classical SIR (Susceptible-Infected-Recovered) model. The SIDHARTHE model distinguish between the diagnosed and undiagnosed cases, which is very important because undiagnosed individuals are more likely to spread the virus than diagnosed individuals. We have stratified the lockdowns and un-lockdowns into seven phases and have computed the basic reproduction number R0 for each phase. We have calibrated our model results with real data from 20 March 2020 to 31 July 2020. Our results demonstrate that different strategies implemented by GoI, have delayed the peak of pandemic by approximately 100 days. But due to underdiagnosis of the infected asymptomatic subpopulation, a sudden outbreak of cases can be observed in India.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No special funding has been provided for this research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
JNU,New Delhi
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.